Pelthos Therapeutics Adds Veteran Finance Executive to Board

An update from Pelthos Therapeutics ( (PTHS) ) is now available.

On December 23, 2025, Pelthos Therapeutics expanded its Board of Directors from seven to eight members and appointed veteran finance executive Andrew J. Einhorn as an independent director, with a term running until the company’s 2026 annual meeting of shareholders. Einhorn, who has more than four decades of experience in investment banking, capital markets and C‑suite finance roles at clinical and commercial-stage life science companies, will serve on Pelthos’ Audit and Compensation Committees and receive standard non-employee director compensation, including a grant of 12,000 restricted stock units vesting on January 1, 2027, and an indemnification agreement consistent with those of other directors and officers. The move brings additional capital markets and strategic financial expertise to Pelthos’ boardroom as the company continues to build out its governance and financial leadership infrastructure following its emergence as a newly public, commercially focused biopharmaceutical company.

The most recent analyst rating on (PTHS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.

More about Pelthos Therapeutics

Pelthos Therapeutics Inc., based in Durham, N.C. and listed on NYSE American, is a biopharmaceutical company focused on commercializing innovative, safe and efficacious therapeutic products for patients with unmet treatment burdens. Its lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum, received U.S. Food and Drug Administration approval in 2024, positioning the company in the dermatology and infectious skin disease treatment market.

Average Trading Volume: 21,704

Technical Sentiment Signal: Buy

Current Market Cap: $79.11M

For a thorough assessment of PTHS stock, go to TipRanks’ Stock Analysis page.